BR112015023161B1 - Derivados de piridin-4-ila - Google Patents

Derivados de piridin-4-ila Download PDF

Info

Publication number
BR112015023161B1
BR112015023161B1 BR112015023161-6A BR112015023161A BR112015023161B1 BR 112015023161 B1 BR112015023161 B1 BR 112015023161B1 BR 112015023161 A BR112015023161 A BR 112015023161A BR 112015023161 B1 BR112015023161 B1 BR 112015023161B1
Authority
BR
Brazil
Prior art keywords
ethyl
oxadiazol
hydroxypropyl
hydroxyacetamide
compound
Prior art date
Application number
BR112015023161-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023161A2 (pt
BR112015023161A8 (pt
Inventor
Martin Bolli
Cyrille Lescop
Oliver Nayler
Beat Steiner
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of BR112015023161A2 publication Critical patent/BR112015023161A2/pt
Publication of BR112015023161A8 publication Critical patent/BR112015023161A8/pt
Publication of BR112015023161B1 publication Critical patent/BR112015023161B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BR112015023161-6A 2013-03-15 2014-03-14 Derivados de piridin-4-ila BR112015023161B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
EP13159482.2 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (3)

Publication Number Publication Date
BR112015023161A2 BR112015023161A2 (pt) 2017-07-18
BR112015023161A8 BR112015023161A8 (pt) 2021-06-22
BR112015023161B1 true BR112015023161B1 (pt) 2022-11-16

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023161-6A BR112015023161B1 (pt) 2013-03-15 2014-03-14 Derivados de piridin-4-ila

Country Status (33)

Country Link
US (1) US9617250B2 (enExample)
EP (1) EP2970236B1 (enExample)
JP (1) JP6387361B2 (enExample)
KR (1) KR102212975B1 (enExample)
CN (1) CN105189487B (enExample)
AR (1) AR095523A1 (enExample)
AU (1) AU2014229217B2 (enExample)
BR (1) BR112015023161B1 (enExample)
CA (1) CA2900910C (enExample)
CL (1) CL2015002620A1 (enExample)
CY (1) CY1119619T1 (enExample)
DK (1) DK2970236T3 (enExample)
EA (1) EA029309B1 (enExample)
ES (1) ES2649475T3 (enExample)
HR (1) HRP20171763T1 (enExample)
HU (1) HUE035154T2 (enExample)
IL (1) IL241363B (enExample)
LT (1) LT2970236T (enExample)
MA (1) MA38482B1 (enExample)
MX (1) MX363545B (enExample)
MY (1) MY173573A (enExample)
NO (1) NO2970236T3 (enExample)
NZ (1) NZ713080A (enExample)
PH (1) PH12015502118B1 (enExample)
PL (1) PL2970236T3 (enExample)
PT (1) PT2970236T (enExample)
SA (1) SA515361104B1 (enExample)
SG (1) SG11201507227UA (enExample)
SI (1) SI2970236T1 (enExample)
TW (1) TWI623534B (enExample)
UA (1) UA115357C2 (enExample)
WO (1) WO2014141171A1 (enExample)
ZA (1) ZA201507657B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
AU2007292993B2 (en) * 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
CA2700917A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
JP2011513385A (ja) 2008-03-06 2011-04-28 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン−ピリジン誘導体
JP5411877B2 (ja) 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
CN102015695B (zh) 2008-03-07 2014-08-27 埃科特莱茵药品有限公司 吡啶-2-基衍生物
JP5481395B2 (ja) 2008-03-07 2014-04-23 アクテリオン ファーマシューティカルズ リミテッド 新規なアミノメチルベンゼン誘導体
AU2009258242B2 (en) * 2008-05-14 2015-07-16 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
EP2403849B1 (en) 2009-03-03 2014-07-16 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
SI2454255T1 (sl) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot agonisti s1p1/edg1
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
KR101869120B1 (ko) 2011-01-19 2018-06-19 이도르시아 파마슈티컬스 리미티드 2-메톡시-피리딘-4-일 유도체

Also Published As

Publication number Publication date
TW201443044A (zh) 2014-11-16
ZA201507657B (en) 2022-08-31
BR112015023161A2 (pt) 2017-07-18
CL2015002620A1 (es) 2016-03-18
JP6387361B2 (ja) 2018-09-05
UA115357C2 (uk) 2017-10-25
WO2014141171A1 (en) 2014-09-18
IL241363B (en) 2018-11-29
EA029309B1 (ru) 2018-03-30
LT2970236T (lt) 2017-11-10
AU2014229217A1 (en) 2015-11-05
SI2970236T1 (sl) 2017-11-30
EP2970236A1 (en) 2016-01-20
PH12015502118A1 (en) 2016-01-25
EA201500931A1 (ru) 2016-03-31
TWI623534B (zh) 2018-05-11
HRP20171763T1 (hr) 2017-12-29
US20160031866A1 (en) 2016-02-04
AR095523A1 (es) 2015-10-21
MA38482A1 (fr) 2017-12-29
PT2970236T (pt) 2017-11-30
DK2970236T3 (en) 2017-10-16
HUE035154T2 (en) 2018-05-02
PL2970236T3 (pl) 2018-01-31
MA38482B1 (fr) 2018-11-30
PH12015502118B1 (en) 2016-01-25
AU2014229217B2 (en) 2017-12-14
CA2900910A1 (en) 2014-09-18
EP2970236B1 (en) 2017-08-30
CA2900910C (en) 2021-03-30
NO2970236T3 (enExample) 2018-01-27
CN105189487A (zh) 2015-12-23
IL241363A0 (en) 2015-11-30
CN105189487B (zh) 2017-12-26
SG11201507227UA (en) 2015-10-29
MX2015012293A (es) 2015-12-16
NZ713080A (en) 2020-06-26
ES2649475T3 (es) 2018-01-12
HK1220454A1 (en) 2017-05-05
KR102212975B1 (ko) 2021-02-05
SA515361104B1 (ar) 2016-06-28
US9617250B2 (en) 2017-04-11
BR112015023161A8 (pt) 2021-06-22
JP2016512227A (ja) 2016-04-25
CY1119619T1 (el) 2018-04-04
KR20150128947A (ko) 2015-11-18
MX363545B (es) 2019-03-27
MY173573A (en) 2020-02-04

Similar Documents

Publication Publication Date Title
BR112015023161B1 (pt) Derivados de piridin-4-ila
EP2069318B1 (en) Phenyl derivatives and their use as immunomodulators
CA2661315C (en) Pyridin-3-yl derivatives as immunomodulating agents
CA2767585C (en) Pyridin-4-yl derivatives
WO2009109907A1 (en) Novel pyrimidine-pyridine derivatives
HK1220454B (en) Pyridin-4-yl derivatives

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.